These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 21496401)
1. Modulation of Toll-like receptors in psoriatic patients during therapy with adalimumab. De Pita O; Nardis C; Lupi F; Luci CA; Frezzolini A; Pallotta S Int J Immunopathol Pharmacol; 2011; 24(1):185-8. PubMed ID: 21496401 [TBL] [Abstract][Full Text] [Related]
2. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Baker BS; Ovigne JM; Powles AV; Corcoran S; Fry L Br J Dermatol; 2003 Apr; 148(4):670-9. PubMed ID: 12752123 [TBL] [Abstract][Full Text] [Related]
3. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299 [TBL] [Abstract][Full Text] [Related]
4. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy. Johansen C; Vinter H; Soegaard-Madsen L; Olsen LR; Steiniche T; Iversen L; Kragballe K Br J Dermatol; 2010 Dec; 163(6):1194-204. PubMed ID: 20846304 [TBL] [Abstract][Full Text] [Related]
5. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Bongiorno MR; Pistone G; Doukaki S; Aricò M Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728 [TBL] [Abstract][Full Text] [Related]
6. Treatment of psoriasis with adalimumab. Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904 [TBL] [Abstract][Full Text] [Related]
8. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729 [TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373 [TBL] [Abstract][Full Text] [Related]
10. [Biological treatment of psoriasis and psoriatic arthritis]. Kragballe K; Deleuran B Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300 [TBL] [Abstract][Full Text] [Related]
11. [How I treat....psoriasis comorbidities by adalimumab (Humira) anti-TNFalpha]. Piérard-Franchimont C; Henry F; Szepetiuk G; Piérard GE Rev Med Liege; 2010 Oct; 65(10):545-8. PubMed ID: 21128358 [TBL] [Abstract][Full Text] [Related]
12. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Vena GA; Galluccio A; De Simone C; Mastrandrea V; Buquicchio R; La Greca S; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pità O; Pezza M; D Agostino M; Vernaci R; Miracapillo A; Valenti G; Cassano N Int J Immunopathol Pharmacol; 2009; 22(1):227-33. PubMed ID: 19309570 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203 [TBL] [Abstract][Full Text] [Related]
14. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. Marble DJ; Gordon KB; Nickoloff BJ J Dermatol Sci; 2007 Nov; 48(2):87-101. PubMed ID: 17689932 [TBL] [Abstract][Full Text] [Related]
15. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies. Barthel C; Biedermann L; Frei P; Vavricka SR; Kündig T; Fried M; Rogler G; Scharl M Digestion; 2014; 89(3):209-15. PubMed ID: 24853251 [TBL] [Abstract][Full Text] [Related]
16. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. Balato A; Schiattarella M; Di Caprio R; Lembo S; Mattii M; Balato N; Ayala F J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1016-24. PubMed ID: 24033358 [TBL] [Abstract][Full Text] [Related]
17. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Revicki DA; Menter A; Feldman S; Kimel M; Harnam N; Willian MK Health Qual Life Outcomes; 2008 Oct; 6():75. PubMed ID: 18831744 [TBL] [Abstract][Full Text] [Related]
18. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Chew AL; Bennett A; Smith CH; Barker J; Kirkham B Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab in the management of palmoplantar psoriasis. Ghate JV; Alspaugh CD Dermatol Online J; 2009 Jul; 15(7):15. PubMed ID: 19903443 [TBL] [Abstract][Full Text] [Related]
20. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. Sánchez-Moya AI; Dauden E J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]